AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 191 min read$NTHI

GARNETT KEITHLY sold $17K of NTHI

GARNETT KEITHLY (CFO) sold 5,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $3.36 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GARNETT KEITHLY
Published Sep 19, 2026, 1:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTHI
Neutral
high confidence
Mentioned
$NTHI
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHINeutralLow
01

Why it matters

The transaction is small and unlikely to affect market perception.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed in the filing.

Relevance 2/10Novelty 4/10Timing: filing date 2026-09-18

Background

Form 4 disclosures are primary sources for insider transactions.

Company-level read

Ticker impact

$NTHINeutralHigh confidence
Context

CFO Garnett Keithly sold 5,000 shares for $16,809 via a Form 4 filing.

Expected impact

No material impact

Evidence & confidence

Sale size is small relative to total holdings and market cap.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a signal of weakness.

Key entities

  • Company
    Neonc Technologies Holdings, Inc.

    Issuer of the Form 4 filing.

  • Executive
    Garnett Keithly

    Chief Financial Officer of Neonc Technologies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTHI insider trading history →

Related articles

AUG 13
$NTHIMed

Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.

finanznachrichten.de4 min
AUG 12
$NTHIMed

WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.

finanznachrichten.de4 min
AUG 12
$NTHIMedAI 8/10

NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market

NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.

rttnews.com4 min
AUG 12
$NTHIHighAI 9/10

Why is Neonc Technologies stock surging today?

Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.

investing.com4 min
AUG 12
$NTHIMedAI 8/10

NeOnc Technologies stock jumps on positive glioma trial data

NeOnc Technologies Holdings (NASDAQ:NTHI) shares rose 11.7% after positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 6-month progression-free survival of 48.9% vs a 20% benchmark (p=0.0047). Median overall survival was 26.09 months; 86.7% were alive at six months. The company plans an FDA Type B meeting.

investing.com4 min